12 Best Healthcare Stocks to Buy According to Analysts

6) Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Number of Hedge Fund Holders: 50

Average Upside Potential: 74%

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. Analyst Gil Blum from Needham maintained a “Buy” rating, maintaining the price target at $202.00. The rating is backed by a combination of factors revolving around positive outcomes from Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s EMBARK study. Notably, the 2-year results from the study exhibited significant improvements throughout various measures of Duchenne muscular dystrophy (DMD), reflecting the potential of ELEVIDYS as a treatment.

Furthermore, the data showcased that older patients in a crossover group witnessed functional gains as compared to younger patients in the original study cohort, implying broad clinical benefit. Notably, Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s FDA-approved gene therapy, ELEVIDYS, supports the company’s significant moat, placing the company in a leadership position in muscle dystrophy treatments. In Q4 2024, the company grew total net product revenue by 75% YoY and grew ELEVIDYS by a strong 112% over the prior sequential quarter.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s total net product revenue came in at $638.2 million for Q4 2024 and $1.79 billion for FY 2024, surpassing the full-year guidance by more than $100 million. The company reiterated its 2025 full-year total net product revenue guidance of $2.9 billion – $3.1 billion.